TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Bisphenol A Exposure, Ovarian Function and Assisted Reproductive Technology Outcome.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Couples attending an IVF or ICSI attempt whose woman is aged 28 ans to 34 at inclusion time~* Regular menstrual cycles (between 27 and 33 days)~* 1st or 2nd IVF or ICSI attempt with an embryo transfer at D2 or D3~Exclusion Criteria:~* couple already included in the study~* ovarian surgery history~* uterine (malformation, diethylstilbestrol (DES) syndrome, adenomyosis...) or systemic pathology that can affect implantation (thrombophilia, antiphospholipids syndrome...)~* chemotherapy history for the woman~* any endocrinopathy (except dysthyroid) in the woman~* any pelvic surgery for the woman in the 3 months preceding inclusion~* endometriosis~* ICSI with testicular sperm~* Positive viral load for HIV, hepatitis C virus or hepatitis B virus (HCV or HBV) during the year preceding inclusion in one or both members of the couple

- Gender: ALL
- Minimum Age: 28 Years
- Maximum Age: 34 Years
- Healthy Volunteers: f

Study Arms:
- couples (Type: EXPERIMENTAL): couples attending an IVF or intra cytoplasmic sperm injection (ICSI) attempt have hormonal and blood analysis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects, ages 18-65~* Chronic HCV infection, defined as having documented HCV infection (antibody or RNA positivity) at least 6 months prior to Baseline (Day 1) with HCV viremia at screening~* Screening Knodell necroinflammatory score \>= 3 based on liver biopsy evaluation (as determined by local pathologist) conducted anytime during the 45-day screening period~* ALT \> the upper limit of the normal range (ULN) but \< 10 X ULN at the screening visit~* Previously failed pegylated interferon-based HCV therapy in combination with ribavirin therapy, or is unable to tolerate or has contraindications to receiving interferon or ribavirin therapy~* BMI between 19 and 36 kg/m2 (inclusive)~* Creatinine clearance \>= 70 mL/min~* absolute neutrophil count \>= 1000/mm3~* Hemoglobin \> 10 g/dL~* Have no clinical or laboratory evidence of hepatic decompensation~Exclusion Criteria:~* Decompensated liver disease~* Child-Pugh grade B or C cirrhosis~* Evidence of hepatocellular carcinoma~* Positive urine drug screen for cocaine or amphetamines~* Infection with HCV genotype 3~* Co-infection with hepatitis B virus or human immunodeficiency virus~* Pancreatitis~* Recent significant infection or symptoms of infection~* Autoimmune disorders~* Any history of seizure~* Is a public transportation operator (pilot of airplane or ship; air traffic controller; bus, train or subway driver) or operates heavy construction machinery~* Transplantation~* History of malignancy~* Current excessive alcohol ingestion, averaging \> 3 drinks/day for females and \> 4 drinks/day for males~* History of or current binge drinking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- GS-9450 10 mg/day (Type: EXPERIMENTAL): GS-9450 taken as one 10 mg capsule by mouth once daily
- GS-9450 40 mg/day (Type: EXPERIMENTAL): GS-9450 taken as one 40 mg capsule by mouth once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo taken as one placebo capsule by mouth once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. For registration: Willing to undergo allogeneic transplantation.~2. For registration: Age equal to or less than 65 years old.~3. For registration: Metastatic RCC with predominant conventional cell type.~4. For registration: Prior nephrectomy.~5. For registration: Stage IV RCC. If patient has prior single brain metastasis treated with complete surgical resection or stereotactic radiation therapy, no recurrence or brain edema from the end of treatment for at least 6 months has to be shown by radiological imaging.~6. For registration: Zubrod performance status \< one.~7. For registration: Potential related donor for allogeneic stem cell transplantation.~8. For registration: At least one prior treatment for metastatic RCC. Radiation therapy or surgery is not counted as a treatment.~9. For registration: Signed an informed consent.~10. For transplantation: Zubrod performance status \< one.~11. For transplantation: An HLA-matched (defined as 6/6 matches) related donor.~12. For transplantation: Failed at least one prior treatment for metastatic RCC. Radiation therapy or surgery is not counted as a treatment.~13. For transplantation: Adequate major organ functions (see section 4.17-4.20).~14. For transplantation: Signed an informed consent for allogeneic stem cell transplantation.~Exclusion Criteria:~1. For registration: Prior history of allogeneic stem cell transplantation.~2. For registration: Histologic feature with predominant non-conventional cell type.~3. For registration: Multiple brain metastasis.~4. For registration: Life expectancy is severely limited by concomitant illness.~5. For transplantation: Multiple brain metastasis.~6. For transplantation: Life expectancy is severely limited by concomitant illness.~7. For transplantation: Clinically significant active infections.~8. For transplantation: HIV infection.~9. For transplantation: Chronic active hepatitis~10. For transplantation: Pregnant or lactating women.~11. For transplantation: Has all three risk factors: high serum lactate dehydrogenase, low hemoglobin, high corrected serum calcium.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Fludarabine + Cyclophosphamide with ASCT (Type: EXPERIMENTAL): ASCT=Allogeneic Hematopoietic Stem Cell Transplantation
- Fludarabine + Melphalan with ASCT (Type: EXPERIMENTAL): ASCT=Allogeneic Hematopoietic Stem Cell Transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Exploratory Study of Norepinephrine to Prevent Radiodermatitis in Breast Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Eligibility Criteria~Subjects must:~* be ≥ age 18 years of age with a documented pathological diagnosis of Stage Ia (T1, N0, M0), Stage Ib (T0 or 1, N1mic, M0) or Stage IIa (T\<3cm, N0, M0) infiltrating ductal or lobular carcinoma of the breast or ductal carcinoma in situ (DCIS).~* be post-surgical patients scheduled to be treated with at least 40 to 50.4 Gy to the whole breast and axilla using either standard or hypofractionated radiation techniques . An additional 10-16 Gy boost to the lumpectomy region may also be delivered. All radiation treatment is to be delivered based on standard CT planning.~* have the ability to understand the informed consent document.~* be able to comply with protocol schedule.~* have a negative serum pregnancy test (within 7 days prior to starting radiation therapy), if a female of child bearing potential.~* consent to utilize medically acceptable methods of contraception throughout the study period if of child-bearing potential.~Exclusion Criteria~Subjects:~* with unhealed surgical wounds or scars in the study treatment area (axilla).~* with underlying active untreated cardiac disease (e.g. arrhythmia).~* with generalized skin disorders that have required treatment within the past 6 months.~* with connective tissue disorders.~* with rashes, ulcerations, or poorly healed scars in the study drug application area (axilla).~* with a known allergy to norepinephrine.~* with known uncontrolled hypertension (repeatedly elevated BP; systolic BP \>139 or diastolic BP \>89).~* with a known clinically significant abnormal ECG within the past 6 months.~* receiving MAO inhibitors or antidepressants (triptyline or imipramine types).~* who are pregnant or breastfeeding.~* with lymphovascular space invasion on pathology.~* with dermal lymphatic invasion on pathology.~* with proximity of the tumor to the overlying skin as evidenced by a distance of less than 5 mm on US or MRI (if performed) and within 2 cm of the anticipated application field~* diagnosis of inflammatory breast cancer.~* receiving chemotherapy other than Herceptin concurrent with the radiation.~* with previous radiation to the breast to be treated.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Norepinephrine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Infliximab in Fistulizing Crohn's Disease on Health Care Resources (Study P04204)(TERMINATED)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Treatment with infliximab for fistulizing CD.~* Administration of at least one infliximab infusion \>=12 months before the chart review.~* 18 years of age or over (men and women).~Exclusion Criteria:~* Subjects not followed for a full year after their first infusion of infliximab.~* Subjects not followed for a full year prior to their first infusion of infliximab.~* Subjects who had participated in clinical studies during the data collection timeframe.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Infliximab (Type: None): Because of the difficulty of finding subjects with exactly the same disease severity, information will be recorded for the time period for up to three years before and for one year after their initial infliximab infusion for comparison of health care costs and utilization prior to infliximab and post infliximab use.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ThromboAblation in Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Electrocardiographic inclusion criteria: (baseline 12-lead ECG recorded at 25 mm/second upon arrival at investigational center)~* STEMI within 12 hours of symptom onset, with ≥ 2 mm ST segment elevation in two or more leads and minimum ≥ 3 mm ST segment elevation in one lead.~Angiographic inclusion criteria after crossing with guidewire:~* IRA is a native coronary artery; and,~* Reference vessel diameter 2.5 - 4.0 mm; and,~* TIMI 0 or 1 flow with any TIMI thrombus grade; or,~* TIMI 2 or 3 flow with TIMI thrombus grade 3 or greater~Exclusion Criteria:~* Patient unwilling or unable to give informed consent~* Previous MI in the distribution of the current IRA~* Previous CABG~* Contraindications to PCI~  * allergy(s) to intended study medications~ * contraindicated for stent implantation~* Active bleeding or coagulopathy~* Patient in cardiogenic shock (\<90mmHg SBP and/or requiring IABP or vasopressors)~* Known left ventricular ejection fraction (EF) \<30%~* Fibrinolytic administered before PCI~* Renal insufficiency (creatinine \>2.0mg/dl)~* Current vitamin K antagonist therapy or known INR \>1.5~* Known thrombocytopenia - platelets \<100,000 cell count~* Patient has Left Bundle Branch Block (LBBB) or pacemaker rhythm~* Known history of hemorrhagic stroke (CVA or TIA) \<2 years before screening~* Known or suspected pregnancy~* Current cancer disease~* Comorbidity where survival is anticipated to be \<1 year.~* No future patient cooperation expected~* Patient is participating in another clinical study~* Patient \<18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ELCA (Type: ACTIVE_COMPARATOR): Laser Thromboablation
- PTCA (Type: ACTIVE_COMPARATOR): PTCA (Direct Stenting)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical, Electrophysiological and Biological Diagnostic Criteria of Sensory Neuronopathies

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A :Patients Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuronopathy.~B :Controls Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuropathy excluding a neuronopathy.~Exclusion Criteria:~* Patient with a sensory-motor neuropathy or incomplete clinical evaluation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patient (Type: None): Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuronopathy.
- control (Type: None): Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuropathy excluding a neuronopathy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Quantifying Oxygen Utilization of Tumors Using Oxygen-Enhanced Molecular MRI

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers will include persons who at the time of scans do not present with known neurological conditions that might impact tissue imaging results~* Patient participants should have suspected or pathology-confirmed diagnosis of a brain tumor (any histological subtype including brain metastases)~* All participants must be able to obtain an MRI scan and must be able to safely breathe high concentrations of oxygen~Exclusion Criteria:~* Participants with contraindications to MRI including metal implants~* Participants who are deemed not able to or not safe to breath high concentrations of oxygen

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Feasibility (ASL,pH-Weighted amine CEST, O2-Weighted SAGE-EPI) (Type: EXPERIMENTAL): Participants undergo ASL perfusion, pH-weighted amine CEST, and oxygen-weighted SAGE-EPI , while breathing normal room air (21% oxygen). Patients then undergo another ASL perfusion, pH-weighted amine CEST, and oxygen-weighted SAGE-EPI while breathing medical grade air (100% oxygen). Total ASL perfusion, pH-weighted amine CEST, and oxygen-weighted SAGE-EPI imaging scan time is 60 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ambulation With Labor Epidural in Obese Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Subjects capable of giving consent Singleton pregnancy Nulliparous (defined as no previous pregnancy beyond 20 weeks 0 days) Gestational age greater than or equal to 37 weeks BMI \> = 35 at time of delivery admission Adult companion available Anticipated vaginal delivery~Exclusion Criteria:~Physical disability precluding ambulation Magnesium Administration Contraindications to neuraxial analgesia Cerclage in current pregnancy Active labor DPE Category III fetal heart tracing Fetal Demise In Utero

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Ambulation (Type: EXPERIMENTAL): Participants in this arm will be encouraged to ambulate with epidural in place.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Implementing Restorative Practices for Youth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Middle school in the school district of study (School district wishes to remain anonymous)~Exclusion Criteria:~* A school that is not a middle school in the school district of study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Usual Care (Type: NO_INTERVENTION): Standard school disciplinary practices.
- Dynamic Adaptation Process (Type: EXPERIMENTAL): Using the Dynamic Adaptation Process, specialist coordinators will convene and lead Implementation Resource Teams (IRTs). With the assistance of expert trainers and coaches, the coordinator-led IRTs will then engage in an iterative process of assessment and planning to build school capacity and implement restorative practices to reduce adverse student outcomes related to discipline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Use of DPP-4 Inhibitors in Short Bowel Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients receiving home parenteral nutrition (HPN) because of short bowel syndrome for at least 12 months~* stable metabolic status~* benign disease~Exclusion Criteria:~* HPN \< 12 months~* metabolically unstable~* cancer as the reason for intestinal failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DPP-4 (Type: EXPERIMENTAL): The administration of the DPP-4 inhibitor in the form of a pill once per day
- NO DPP (Type: NO_INTERVENTION): no therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed the 8-week double-blind treatment period of study LYC-30937-2001~* Male and females of childbearing potential must agree to use adequate birth control during the study and for 30 days after discontinuing study drug~* Non-pregnant, non-lactating females who are not planning to become pregnant while enrolled in this study~* Investigator considers it safe and potentially beneficial to participate~* Ability to provide written informed consent and to be compliant with study schedule~Exclusion Criteria:~* Subjects who completed study LYC-30937-2001, but who experienced a serious adverse event that was considered related to investigational product, has an unstable medical condition, or for any other reason in the opinion of the investigator should not participate in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- LYC-30937-EC (Type: EXPERIMENTAL): LYC-30937-EC 25 mg by mouth once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy